Archive · 27 May 2025
FDA Approves Sanofi's Meningococcal Vaccine for Infants
The FDA has approved Sanofi's new vaccine, MenQuadfi, for infants as young as six weeks old.
This vaccine helps protect against serious illnesses caused by meningococcal bacteria.
The approval is based on studies showing the vaccine is safe and effective.
Meningococcal infections can lead to dangerous conditions like blood infections and brain swelling.
While not a routine vaccine for all infants, the CDC recommends it for those at higher risk.
Currently, adolescents get the vaccine, with a booster later on.
Last year saw the highest number of meningococcal disease cases since 2013.
The FDA approved Sanofi's meningococcal vaccine, MenQuadfi, for infants.
The vaccine is approved for infants as young as six weeks old.
It protects against four common strains of meningococcal bacteria.
Approval was based on studies involving over 6,000 participants.
The CDC recommends the vaccine for at-risk individuals and adolescents.
- Who
- The FDA, Sanofi, infants, and individuals at increased risk of the disease.
- What
- The FDA approved Sanofi's MenQuadfi vaccine.
- When
- The approval was announced in May 2025.
- Where
- The U.S.
- Why
- To protect against serious infections caused by meningococcal bacteria.
- Company
- Sanofi
- Vaccine Brand Name
- MenQuadfi
- Age for use
- Six weeks
- Protection against
- Meningococcal bacteria strains A, C, W, and Y
- Participants in studies
- More than 6,000
- Confirmed cases of meningococcal disease in the last year
- 503